Premium
Osteoarthritis‐alleviating effects in papain‐induced model rats of chicken cartilage hydrolysate and its peptide fractions
Author(s) -
Yang Jingyi,
SunWaterhouse Dongxiao,
Xiao Yu,
He Weiwei,
Zhao Mouming,
Su Guowan
Publication year - 2019
Publication title -
international journal of food science and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.831
H-Index - 96
eISSN - 1365-2621
pISSN - 0950-5423
DOI - 10.1111/ijfs.14182
Subject(s) - hydrolysate , chemistry , papain , osteoarthritis , antioxidant , peptide , in vitro , pharmacology , cartilage , trypsin , ultrafiltration (renal) , biochemistry , medicine , enzyme , hydrolysis , pathology , anatomy , alternative medicine
Summary This study aims to discover natural bioactive substances as alternative therapies to current medical and surgical treatments for o steoarthritis ( OA ). Chicken cartilage hydrolysate ( CCH ) was produced using trypsin and separated via ultrafiltration into CCH ‐I (molecular weight ( MW ) > 10 kD a) and CCH ‐ II ( MW <10 kDa). Results showed that CCH and its fractions ( CCH ‐I and CCH ‐ II ) could relieve OA with different extents, and the outcome using these treatments depended on their especial composition. CCH ‐ II (a fraction rich in low MW peptides with no chondroitin sulphate ( CS ) and low in sugar) exhibited desired OA ‐alleviating effect in papain‐induced rat and highest in vitro antioxidant activities. CCH ‐I (a fraction rich in CS and in high MW peptides) might have an adverse effect on renal function. Therefore, it is industrially feasible to produce anti‐inflammatory and antioxidative CCH , especially CCH ‐ II , with the therapeutic potential for alleviating or treating OA . Further separation of CS from CCH ‐I may lead to a commercial pure CS product for treating OA.